Teva Pharmaceutical Industries (TEVA) Raw Materials (2010 - 2018)

Teva Pharmaceutical Industries has disclosed Raw Materials across 9 years of filings, most recently posting $1.3 billion for Q4 2018.

• Quarterly Raw Materials fell 8.67% year-over-year to $1.3 billion in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $1.3 billion (down 8.67% YoY) and the FY2018 annual result came in at $1.3 billion, down 8.67% from the prior year.
• Raw Materials eased to $1.3 billion in Q4 2018, from $1.4 billion in the prior quarter.
• Over five years, Raw Materials peaked at $1.5 billion in Q1 2018 and troughed at $1.2 billion in Q4 2015.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2016 frame the typical range for Raw Materials.
• Annual changes were most pronounced in 2014 — Raw Materials slipped 18.85% — and 2016, when it climbed 15.9%.
• Tracing TEVA's Raw Materials over 5 years: stood at $1.3 billion in 2014, then retreated by 6.57% to $1.2 billion in 2015, then advanced by 15.9% to $1.4 billion in 2016, then climbed by 4.98% to $1.5 billion in 2017, then fell by 8.67% to $1.3 billion in 2018.
• Business Quant data shows TEVA's Raw Materials at $1.3 billion in Q4 2018, $1.4 billion in Q3 2018, and $1.4 billion in Q2 2018.